Clinical pharmacokinetics of antibacterial agents in pre-term infants

Reviews and Research in Medical Microbiology

Volumn 7, Issue 4, 1996, Pages 179-194

  Van Den Anker, John N ^a,b   De Groot, Ronald ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Antibacterial agents; Antibiotics; Neonatal intensive care; Pharmacokinetics; Pre term infants; Premature baby

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; ERYTHROMYCIN; MEROPENEM; METRONIDAZOLE; PENICILLIN DERIVATIVE; UNINDEXED DRUG; VANCOMYCIN;

BACTERIAL INFECTION; BLEEDING; BLOOD DISEASE; BODY COMPOSITION; BONE MARROW DEPRESSION; DISEASE SEVERITY; DRUG CLEARANCE; DRUG COST; DRUG DISPOSITION; DRUG HALF LIFE; DRUG TOXICITY; DRUG USE; HUMAN; HYPOXEMIA; INTRAVENOUS DRUG ADMINISTRATION; LIVER DISEASE; LIVER TOXICITY; MORBIDITY; MORTALITY; NEPHROTOXICITY; NEUROTOXICITY; NEWBORN; NEWBORN INTENSIVE CARE; NEWBORN PERIOD; OTOTOXICITY; PREGNANCY; PREMATURITY; PRIORITY JOURNAL; RASH; REVIEW; STEVENS JOHNSON SYNDROME;

EID: 0029806518     PISSN: 0954139X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00013542-199610000-00001     Document Type: Review

References (138)

1. Remington JS, Klein, JO, eds: Infectious diseases of the fetus and newborn infant, 4th edn. Philadelphia: Saunders, 1995.
2. St Geme JW 3rd, Polin RA. Neonatal sepsis. Progress in diagnosis and management. Drugs 1988; 36: 784-800.
3. Fanaroff AA, Korones SB, Wright LL, et al. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. N Engl J Med 1994; 330: 1107-1113.
4. Baker CJ, Melish ME, Hall RT, Casto DT, Vasan U, Givner LB. Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. N Engl J Med 1992; 327: 213-219.
5. Gladstone IM, Ehrenkranz RA, Edberg SC, Baltimore RS. A ten-year review of neonatal sepsis and comparison with the previous fifty-year experience. Pediatr Infect Dis J 1990; 9: 819-825.
6. Escobar GJ, Zukin T, Usatin MS, et al. Early discontinuation of antibiotic treatment in newborns admitted to rule out sepsis: a decision rule. Pediatr Infect Dis J 1994; 13: 860-866.
7. Anonymous. Early neonatal drug utilization in preterm newborns in neonatal intensive care units. Italian Collaborative Group on Preterm Delivery. Dev Pharmacol Ther 1988; 11: 1-7.
8. Besunder JB, Reed MD, Blumer JL. Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part 1). Clin Pharmacokinet 1988; 14: 189-216.
9. Bradley JS. Neonatal infections. Pediatr Infect Dis 1985; 4: 315-320.
10. Prober CG, Stevenson DK, Benitz WE. The use of antibiotics in neonates weighing less than 1200 grams. Pediatr Infect Dis J 1990; 9: 111-121.
11. Parini R, Rusconi F, Cavanna G, Vigliani E, Cornacchia L, Assael BM. Evaluation of the renal and auditory function of neonates treated with amikacin. Dev Pharmacol Ther 1982; 5: 33-46.
12. Granati B, Assael BM, Chung M, et al. Clinical pharmacology of netilmicin in preterm and term newborn infants. J Pediatr 1985; 106: 664-669.
13. Adelman RD, Wirth F, Rubio T. A controlled study of the nephrotoxicity of mezlocillin and amikacin in the neonate. Am J Dis Child 1987; 141: 1175-1178.
14. Elinder G, Aperia A. Development of glomerular filtration rate and excretion of p2-microglobulin in neonates during gentamicin treatment. Acta Paediatr Scand 1983; 72: 219-224.
15. Zarfin Y, Koren G, Maresky D, Perlman M, Macleod S. Possible indomethacin-amino-glycoside interaction in preterm infants. J Pediatr 1985; 106: 511-513.
16. Reed MD, Vermeulen MW, Stern RC, Cheng PW, Powell SH, Boat TF. Are measurements of urine enzymes useful during aminoglycoside therapy? Pediatr Res 1981; 15: 1234-1239.
17. Rajchgot P, Prober CG, Soldin S. et al. Aminoglycoside-related nephrotoxicity in the premature newborn. Clin Pharmacol Ther 1984; 35: 394-401.
18. Marre R, Tarara N, Louton T, Sack K. Age-dependent nephrotoxicity and the pharmacokinetics of gentamicin in rats. Eur J Pediatr 1980; 133: 25-29.
19. Smith, CR, Baughman KL, Edwards CQ, Rogers JF, Lietman PS. Controlled comparison of amikacin and gentamicin. N Engl J Med 1977; 296: 349-353.
20. Smith CR, Lipsky JJ, Laskin OL, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980; 302: 1106-1109.
21. Lerner AM, Reyes MP, Cone LA, et al. Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet 1983; 1: 1123-1126.
22. Gatell JM, SanMiguel JG, Araujo V, et al. Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin. Antimicrob Agents Chemother 1984; 26: 766-769.
23. Finitzo-Hieber T, McCracken GH Jr, Brown KC. Prospective, controlled evaluation of auditory function in neonates given netilmicin or amikacin. J Pediatr 1985; 106: 129-136.
24. Kildoo C, Modanlou HD, Komatsu G, Harralson A, Hodding J. Developmental pattern of gentamicin kinetics in very low birth weight (VLBW) sick infants. Dev Pharmacol Ther 1984; 7: 345-356.
25. Koren G, Leeder S, Harding E, Jacques D, MacLeod SM. Optimization of gentamicin therapy in very low birth weight infants. Pediatr Pharmacol (New York) 1985; 5: 79-87.
26. Landers S, Berry PL, Kearns GL, Kaplan SL, Rudolph AJ. Gentamicin disposition and effect on development of renal function in the very low birth weight infant. Dev Pharmacol Ther 1984; 7: 285-302.
27. Nahata MC, Powell DA, Gregoire RP, et al. Tobramycin kinetics in newborn infants. J Pediatr 1983; 103: 136-138.
28. Nahata MC, Powell DA, Durrell DE, Miller MC, Glazer JP. Effect of gestational age and birth weight on tobramycin kinetics in newborn infants. J Antimicrob Chemother 1984; 14: 59-65.
29. Nahata MC, Powell DA, Durrell DE, Miller MA. Tobramycin pharmacokinetics in very low birth weight infants. Br J Clin Pharmacol 1986; 21: 325-327.
30. Kuhn RJ, Nahata MC, Powell DA, Bickers RG. Pharmacokinetics of netilmicin in premature infants. Eur J Clin Pharmacol 1986; 29: 635-637.
31. Kenyon CF, Knoppert DC, Lee SK, Vandenberghe HM, Chance GW. Amikacin pharmacokinetics and suggested dosage modifications for the preterm infant. Antimicrob Agents Chemother 1990; 34: 265-268.
32. Szefler SJ, Wynn RJ, Clarke DF, Buckwald S, Shen D, Schentag JJ. Relationship of gentamicin serum concentrations to gestational age in preterm and term neonates. J Pediatr 1980; 97: 312-315.
33. Hindmarsh KW, Nation RL, Williams GL, John E, French JN. Pharmacokinetics of gentamicin in very low birth weight preterm infants. Eur J Clin Pharmacol 1983; 24: 649-653.
34. Husson C, Chevalier JY, Jezequel M, Mathe JC, Costil J, Aymard P. Pharmacokinetic study of gentamicin in preterm and term neonates. Dev Pharmacol Ther 1984; 7 Suppl 1: 125-129.
35. Kasik JW, Jenkins S, Leuschen MP, Nelson RM Jr. Postconceptional age and gentamicin elimination half-life. J Pediatr 1985; 106: 502-505.
36. Friedman CA, Parks BR, Rawson JE. Gentamicin disposition in asphyxiated newborns: relationship to mean arterial blood pressure and urine output. Pediatr Pharmacol (New York) 1982; 2: 189-197.
37. Watterberg KL, Kelly HW, Johnson JD, Aldrich M, Angelus P. Effect of patent ductus arteriosus on gentamicin pharmacokinetics in very low birth weight (<1500 g) babies. Dev Pharmacol Ther 1987; 10: 107-117.
38. Arbeter AM, Saccar CL, Eisner S, Sarni E, Yaffe SJ. Tobramycin sulfate elimination in premature infants. J Pediatr 1983; 103: 131-135.
39. Siegel JD, McCracken GH Jr, Thomas ML, Threlkeld N. Pharmacokinetic properties of netilmicin in newborn infants. Antimicrob Agents Chemother 1979; 15: 246-253.
40. Howard JB, McCracken GH Jr, Trujillo H, Mohs E. Amikacin in newborn infants: comparative pharmacology with kanamycin and clinical efficacy in 45 neonates with bacterial diseases. Antimicrob Agents Chemother 1976; 10: 205-210.
41. Myers MG, Roberts RJ, Mirhij NJ. Effects of gestational age, birth weight, and hypoxemia on pharmacokinetics of amikacin in serum of infants. Antimicrob Agents Chemother 1977; 11: 1027-1032.
42. McCracken GH Jr, Mize SG. A controlled study of intrathecal antibiotic therapy in gram-negative enteric meningitis of infancy. Report of the Neonatal Meningitis Cooperative Study Group. J Pediatr 1976; 89: 66-72.
43. McCracken GH Jr, Mize SG, Threlkeld N. Intraventricular gentamicin therapy in gram-negative bacillary meningitis of infancy. Report of the Second Neonatal Meningitis Co-operative Study Group. Lancet 1980; i: 787-791.
44. Van den Anker JN, Hop WC, De Groot R, et al. Effects of prenatal exposure to betamethasone and indomethacin on the glomerular filtration rate in the preterm infant. Pediatr Res 1994; 36: 578-581.
45. Leake RD, Trygstad CW, Oh W. Inulin clearance in the newborn infant: relationship to gestational and postnatal age. Pediatr Res 1976; 10: 759-762.
46. Van der Heijden AJ, Grose WF, Ambagtsheer JJ, Provoost AP, Wolff ED, Sauer PJ. Glomerular filtration rate in the preterm infant: the relation to gestational and postnatal age. Eur J Pediatr 1988; 148: 24-28.
47. Zarowitz BJ, Wynn RJ, Buckwald S, Szefler SJ. High gentamicin trough concentrations in neonates of less than 28 weeks gestational age. Dev Pharmacol Ther 1982; 5: 68-75.
48. Charlton CK, Needelman H, Thomas RW, Kortas K. Gentamicin dosage recommendations for neonates based on half-life predictions from birth weight. Am J Perinatol 1986; 3: 28-32.
49. Cordero L, Arwood L, DeCenzo S, Visconti J. Serum netilmicin levels in premature AGA infants. Am J Perinatol 1987; 4: 36-40.
50. Phillips AM, Milner RD. Clinical pharmacology of netilmicin in the newborn. Arch Dis Child 1983; 58: 451-453.
51. Placzek M, Whitelaw A, Want S, Sahathevan M, Darrell J. Piperacillin in early neonatal infection. Arch Dis Child 1983; 58: 1006-1009.
52. Siegel SR, Oh W. Renal function as a marker of human fetal maturation. Acta Paediatr Scand 1976; 65: 481-485.
53. Stonestreet BS, Rubin L, Pollak A, Cowett RM, Oh W. Renal functions of low birth weight infants with hyperglycemia and glucosuria produced by glucose infusions. Pediatrics 1980; 66: 561-567.
54. Mustafa MM, Mertsola J, Ramilo O, Saez-Llorens X, Risser RC, McCracken GH Jr. Increased endotoxin and interleukin-1β concentrations in cerebrospinal fluid of infants with coliform meningitis and ventriculitis associated with intraventricular gentamicin therapy. J Infect Dis 1989; 160: 891-895.
55. Dahl LB, Melby K, Gutteberg TJ, Storvold G. Serum levels of ampicillin and gentamicin in neonates of varying gestational age. Eur J Pediatr 1986; 145: 218-221.
56. Huisman-de Boer JJ, Van den Anker JN, Vogel M, Goessens WH, Schoemaker RC, De Groot R. Amoxicillin pharmacokinetics in preterm infants with gestational ages of less than 32 weeks. Antimicrob Agents Chemother 1995; 39: 431-434.
57. Banner W Jr, Gooch WM 3rd, Burckart G, Korones SB. Pharmacokinetics of nafcillin in infants with low birth weights. Antimicrob Agents Chemother 1980; 17: 691-694.
58. Nelson JD, Shelton S, Kusmiesz H. Clinical pharmacology of ticarcillin in the newborn infant: relation to age, gestational age, and weight. J Pediatr 1975; 87: 474-479.
59. Kacet N, Roussel-Delvallez M, Gremillet C, Dubos JP, Storme L, Lequien P. Pharmacokinetic study of piperacillin in newborns relating to gestational and postnatal age. Pediatr Infect Dis J 1992; 11: 365-369.
60. McCracken GH Jr, Ginsberg C, Chrane DF, Thomas ML, Horton LJ. Clinical pharmacology of penicillin in newborn infants. J Pediatr 1973; 82: 692-698.
61. Boe RW, Williams CP, Bennett JV, Oliver TK Jr. Serum levels of methicillin and ampicillin in newborn and premature infants in relation to postnatal age. Pediatrics 1967; 39: 194-201.
62. Sarff LD, McCracken GH Jr, Thomas ML, Horton LJ, Threlkeld N. Clinical pharmacology of methicillin in neonates. J Pediatr 1977; 90: 1005-1008.
63. O'Connor WJ, Warren GH, Edrada LS, Mandal PS, Rosenman SB. Serum concentrations of sodium nafcillin in infants during the perinatal period. Antimicrob Agents Chemother 1965; 5: 220-222.
64. Morehead CD, Shelton S, Kusmiesz H, Nelson JD. Pharmacokinetics of carbenicillin in neonates of normal and low birth weight. Antimicrob Agents Chemother 1972; 2: 267-271.
65. Fayed SB, Sutton AM, Turner TL, McAllister TA. The prophylactic use of ticarcillin/clavulanate in the neonate. J Antimicrob Chemother 1987; 19: 113-118.
66. Odio C, Threlkeld N, Thomas ML, McCracken GH Jr. Pharmacokinetic properties of mezlocillin in newborn infants. Antimicrob Agents Chemother 1984; 25: 556-559.
67. Jungbluth GL, Wirth FH Jr, Rubio TT, Jamicke DM, Jusko WJ. Developmental pharmacokinetics of mezlocillin in 4 newborn infants. Dev Pharmacol Ther 1988; 11: 317-321.
68. Hieber JP, Nelson JD. A pharmacologic evaluation of penicillin in children with purulent meningitis. N Engl J Med 1977; 297: 410-413.
69. Kaplan JM, McCracken GH Jr, Horton LJ, Thomas ML, Davis N. Pharmacologic studies in neonates given large dosages of ampicillin. J Pediatr 1974; 84: 571-577.
70. Weingärtner L. Clinical aspects of mezlocillin therapy in childhood. J Antimicrob Chemother 1982; 9 Suppl A: 257-262.
71. Chiu T, Garrison RD, Fakhreddine F, Ayoub EM. Mezlocillin in neonatal infections: evaluation on efficacy and toxicity. J Antimicrob Chemother 1982; 9 Suppl A: 251-255.
72. Chamberlain J, Coombes JD, Dell D, et al. Metabolism of cefotaxime in animals and man. J Antimicrob Chemother 1980; 6 Suppl A: 69-78.
73. Jacobs RF, Kearns GL. Cefotaxime and desacetylcefotaxime in neonates and children: a review of microbiologic, pharmacokinetic, and clinical experience. Diagn Microbiol Infect Dis 1989; 12: 93-99.
74. Jones RN, Barry AL, Thornsberry C. Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy. Rev Infect Dis 1982; 4: S366-S373.
75. Schaad UB. The cephalosporin compounds in severe neonatal infection. Eur J Pediatr 1984; 141: 143-146.
76. Bryan CS, John JF Jr, Pai MS, Austin TL. Gentamicin vs cefotaxime for therapy of neonatal sepsis. Relationship to drug resistance. Am J Dis Child 1985; 139: 1086-1089.
77. Aujard Y, Brion F, Jacqz-Aigrain E, et al. Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in the newborn [published erratum appears in Diagn Microbiol Infect Dis 1991; 14: 189-190]. Diag Microbiol Infect Dis 1989; 12: 87-91.
78. Kearns GL, Jacobs RF, Thomas BR, Darville TL, Trang JM. Cefotaxime and desacetyl-cefotaxime pharmacokinetics in very low birth weight neonates. J Pediatr 1989; 114: 461-467.
79. Gouyon JB, Pechinot A, Safran C, Chretien P, Sandre D, Kazmierczak A. Pharmacokinetics of cefotaxime in preterm infants. Dev Pharmacol Ther 1990; 14: 29-34.
80. McCracken GH Jr, Siegel JD, Threlkeld N, Thomas M. Ceftriaxone pharmacokinetics in newborn infants. Antimicrob Agents Chemother 1983; 23: 341-343.
81. McCracken GH Jr, Threlkeld N, Thomas ML. Pharmacokinetics of ceftazidime in newborn infants. Antimicrob Agents Chemother 1984; 26: 583-584.
82. Van den Anker JN, Schoemaker RC, Hop WC, et al. Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age. Clin Pharmacol Ther 1995; 58: 650-659.
83. Van den Anker JN, Hop WC, Schoemaker RC, Van der Heijden AJ, Neijens HJ, De Groot R. Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. Br J Clin Pharmacol 1995; 40: 439-143.
84. Van den Anker JN, Schoemaker RC, Ven der Heijden AJ, Broerse HM, Neijens HJ, De Groot R. Once-daily versus twice-daily administration of ceftazidime in the preterm infant. Antimicrob Agents Chemother 1995; 39: 2048-2050.
85. Kafetzis DA, Brater DC, Kapiki AN, Papas CV, Dellagrammaticas H, Papadatos CJ. Treatment of severe neonatal infections with cefotaxime. Efficacy and pharmacokinetics. J Pediatr 1982; 100: 483-489.
86. McCracken GH Jr, Threlkeld N, Thomas ML. Pharmacokinetics of cefotaxime in newborn infants. Antimicrob Agents Chemother 1982; 21: 683-684.
87. Baird-Lambert J, Doyle PE, Thomas D, Cvejic M, Buchanan N. Pharmacokinetics of cefotaxime in neonates. J Antimicrob Chemother 1984; 13: 471-477.
88. Mulhall A, De Louvois J. The pharmacokinetics and safety of ceftazidime in the neonate. J Antimicrob Chemother 1985; 15: 97-103.
89. Prinsloo JG, Delpot SD, Moncrieff J, Paton AM. A preliminary pharmacokinetic study of ceftazidime in premature, newborn and small infants. J Antimicrob Chemother 1983; 12 Suppl A: 361-364.
90. Van den Anker JN, Van der Heijden AJ, Hop WC, et al. The effect of asphyxia on the pharmacokinetics of ceftazidime in the term newborn. Pediatr Res 1995; 38: 808-811.
91. Martin E, Koup JR, Paravicini U, Stoeckel K. Pharmacokinetics of ceftriaxone in neonates and infants with meningitis. J Pediatr 1984; 105: 475-481.
92. Schaad UB, Hayton WL, Stoeckel K. Single-dose ceftriaxone kinetics in the newborn. Clin Pharmacol Ther 1985; 37: 522-528.
93. Mulhall A, De Louvois J, James J. Pharmacokinetics and safety of ceftriaxone in the neonate. Eur J Pediatr 1985; 144: 379-382.
94. Low DC, Bissenden JG, Wise R. Ceftazidime in neonatal infections. Arch Dis Child 1985; 60: 360-364.
95. Blumer JL, Aronoff SC, Myers CM, O'Brien CA, Klinger JD, Reed MD. Pharmacokinetics and cerebrospinal fluid penetration of ceftazidime in children with meningitis. Dev Pharmacol Ther 1985; 8: 219-231.
96. Van den Anker JN, Broerse HM, Westgeest CD, De Groot R. Cerebrospinal fluid levels of ceftazidime in the preterm neonate. In: Einhorn J, Nord CE, Norrby SR, eds. Recent advances in chemotherapy. Proceedings of the 18th International Congress of Chemotherapy; 1993; Stockholm. Washington, DC: American Society for Microbiology, 1994: 406-407.
97. Del Rio M, McCracken GH Jr, Nelson JD, Chrane D, Shelton S. Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatricpatients with bacterial meningitis. Antimicrob Agents Chemother 1982; 22: 622-627.
98. Latif R, Dajani AS. Ceftriaxone diffusion into cerebrospinal fluid of children with meningitis. Antimicrob Agents Chemother 1983; 23: 46-48.
99. Aronoff GR, Sloan RS, Dinwiddie CB Jr, Glant MD, Fineberg NS, Luft FC. Effects of vancomycin on renal function in rats. Antimicrob Agents Chemother 1981; 19: 306-308.
100. Wood CA, Kohlhepp SJ, Kohnen PW, Houghton DC, Gilbert DN. Vancomycin enhancement of experimental tobramycin nephrotoxicity. Antimicrob Agents Chemother 1986; 30: 20-24.
101. Brummett RE, Fox KE. Vancomycin- and erythromycin-induced hearing loss in humans. Antimicrob Agents Chemother 1989; 33: 791-796.
102. Schaad UB, McCracken GH Jr, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980; 96: 119-126.
103. Reed MD, Kliegman RM, Weiner JS, Huang M, Yamashita TS, Blumer JL. The clinical pharmacology of vancomycin in seriously ill preterm infants. Pediatr Res 1987; 22: 360-363.
104. Lisby-Sutch SM, Nahata MC. Dosage guidelines for the use of vancomycin based on its pharmacokinetcs in infants. Eur J Clin Pharmacol 1988; 35: 637-642.
105. Gross JR, Kaplan SL, Kramer WG, Mason EO Jr. Vancomycin pharmacokinetics in premature infants. Pediatr Pharmacol (New York) 1985; 5: 17-22.
106. Leonard MB, Koren G, Stevenson DK, Prober CG. Vancomycin pharmacokinetcs in very low birth weight neonates. Pediatr Infect Dis J 1989; 8: 282-286.
107. Kildoo CW, Lin LM, Gabriel MH, Folli HL, Modanlou HD. Vancomycin pharmacokinetics in infants: relationship to postconceptional age and serum creatinine. Dev Pharmacol Ther 1990; 14: 77-83.
108. James A, Koren G, Milliken J, Soldin S, Prober C. Vancomycin pharmacokinetics and dose recommendations for preterm infants. Antimicrob Agents Chemother 1987; 31: 52-54.
109. Schaible DH, Rocci ML JR, Alpert GA, et al. Vancomycin pharmacokinetics in infants: relationships to indices of maturation. Pediatr Infect Dis 1986; 5: 304-308.
110. Naqvi SH, Keenan WJ, Reichley RM, Fortune KP. Vancomycin pharmacokinetics in small, seriously ill infants. Am J Dis Child 1986; 140: 107-110.
111. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994; 18: 533-543.
112. Moellering RC Jr. Monitoring serum vancomycin levels: climbing the mountain because it is there? [published erratum appears in Clin Infect Dis 1994; 19: 379]. Clin Infect Dis 1994; 18: 544-546.
113. Saunders NJ. Why monitor peak vancomycin concentrations? Lancet 1994; 344: 1748-1750.
114. De Hoog M, Mouton JW, Van den Anker JN. Why monitor peak vancomycin concentrations? Lancet 1995; 345: 646.
115. Umana MA, Odio CM, Castro E, Salas JL, McCracken GH Jr. Evaluation of aztreonam and ampicillin vs. amikacin and ampicillin for treatment of neonatal bacterial infections. Pediatr Infect Dis J 1990; 9: 175-180.
116. Uauy R, Mize C, Argyle C, McCracken G Jr. Metabolic tolerance to arginine: implications for the safe use of arginine salt-aztreonam combination in the neonatal period. J Pediatr 1991; 118: 965-970.
117. Cuzzolin L, Fanos V, Zambreri D, Padovani EM, Benoni G. Pharmacokinetics and renal tolerance of aztreonam in premature infants. Antimicrob Agents Chemother 1991; 35: 1726-1728.
118. Stutman HR, Marks MI, Swabb EA. Single-dose pharmacokinetics of aztreonam in pediatric patients. Antimicrob Agents Chemother 1984; 26: 196-199.
119. Likitnukul S, McCracken GH Jr, Threlkeld N, Darabi A, Olsen K. Pharmacokinetics and plasma bactericidal activity of aztreonam in low-birth-weight infants. Antimicrob Agents Chemother 1987; 31: 81-83.
120. Jacobs RF. Imipenem-cilastatin: the first thienamycin antibiotic. Pediatr Infect Dis 1986; 5: 444-148.
121. Wong VK, Wright HT Jr, Ross LA, Mason WH, Inderlied CB, Kim KS. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991; 10: 122-125.
122. Reed MD, Kliegman RM, Yamashita TS, Myers CM, Blumer JL. Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life. Antimicrob Agents Chemother 1990; 34: 1172-1177.
123. Freij BJ, McCracken GH Jr, Olsen KD, Threlkeld N. Pharmacokinetics of imipenem-cilastatin in neonates. Antimicrob Agents Chemother 1985; 27: 431-435.
124. Gruber WC, Rench MA, Garcia-Prats JA, Edwards MS, Baker CJ. Single-dose pharmacokinetics of imipenemcilastatin in neonates. Antimicrob Agents Chemother 1985; 27: 511-514.
125. De Groot R, Martinkova J, Chladek J, Kinzig M, Sörgel F. Pharmacokinetics of meropenem in preterm and fullterm neonates. In: American Society for Microbiology. Antimicrobial agents and chemotherapy: program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994, Florida. Washington, DC: American Society for Microbiology, 1994: A71.
126. Dagan R, Velghe L, Rodda JL, Klugman KP. Penetration of meropenem into cerebrospinal fluid of patients with inflamed meninges. J Antimicrob Chemother 1994; 34: 175-179.
127. Brogden RN, Heel RC, Speight TM, Avery GS. Metronidazole in anaerobic infections: a review of its activity, pharmacokinetics and therapeutic use. Drugs 1978; 16: 387-417.
128. Jager-Roman E, Doyle PE, Baird-Lambert J, Cvejic M, Buchanan N. Pharmacokinetics and tissue distribution of metronidazole in the newborn infant. J Pediatr 1982; 100: 651-654.
129. Hall P, Kaye CM, McIntosh N, Steele J. Intravenous metronidazole in the newborn. Arch Dis Child 1983; 58: 529-531.
130. Koren G, Zarfin Y, Maresky D, Spiro TE, MacLeod SM. Pharmacokinetics of intravenous clindamycin in newborn infants. Pediatr Pharmacol (New York) 1986; 5: 287-292.
131. Bell MJ, Shackelford P, Smith R, Schroeder K. Pharmacokinetics of clindamycin phosphate in the first year of life. J Pediatr 1984; 105: 482-486.
132. Waites KB, Crouse DT, Cassell GH. Therapeutic considerations for Ureaplasma urealyticum infections in neonates. Clin Infect Dis 1993; 17: S208-S214.
133. Farrar HC, Walsh-Sukys MC, Kyllonon K, Blumer JL. Cardiac toxicity associated with intravenous erythromycin lactobionate: two case reports and a review of the literature. Pediatr Infect Dis J 1993; 12: 688-691.
134. Waites KB, Sims PJ, Crouse DT, et al. Serum concentrations of erythromycin after intravenous infusion in preterm neonates treated for Ureaplasma urealyticum infection. Pediatr Infect Dis J 1994; 13: 287-293.
135. Ludden TM. Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet 1985; 10: 63-79.
136. Burns L, Hodgman J. Studies of prematures given erythromycin estolate. Am J Dis Child 1963; 106: 280-288.
137. Patamasucon P, Kaojarern S, Kusmiesz H, Nelson JD. Pharmacokinetics of erythromycin ethylsuccinate and estolate in infants under 4 months of age. Antimicrob Agents Chemother 1981; 19: 736-739.
138. Paap CM, Nahata MC. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin Pharmacokinet 1990; 19: 280-318.